ArticleFrontiers in cellular and infection microbiology2025
Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study in China.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The efficacy and safety of colistimethate sodium in the treatment of carbapenem-resistant Gram-negative bacilli: a real-world observational study.Frontiers in cellular and infection microbiology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Patients afflicted with hematological diseases are at an elevated risk of infection, with the potential for the development of sepsis. This study aims to analyze the effectiveness and safety of colistimethate sodium (CMS) in the management of sepsis in Chinese patients with hematological diseases. Methods: A retrospective study was conducted on hematological diseases patients diagnosed as sepsis and treated with CMS at the First Affiliated Hospital of Soochow University between November 2021 and July 2023. Demographics, clinical presentation, causative organisms, clinical outcomes and adverse events (AEs) were recorded. The univariate and multivariate analysis was conducted to identify predictive factors for clinical effectiveness and renal insufficiency. Results: A total of 81 hematological patients diagnosed with sepsis were included, the mean (change in sequential organ failure assessment [SOFA] score) ΔSOFA when utilizing CMS was 3.90 ± 2.10. Following CMS treatment, a clinical effectiveness rate was observed in 62.96% of patients, while the bacteriological eradication rate was 60.23%. Additionally, the 28-day all-cause mortality rate was 29.63%. The median length of stay in the ICU and total in-hospital stay was 13.5 and 33 days, respectively. AEs were reported in 16 patients (19.75%), including 15 (18.52%) renal insufficiency, 1 (1.23%) hepatic insufficiency, and 1 (1.23%) rash. The multivariate analysis of clinical effectiveness indicated that a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score, a higher Charlson comorbidity index, the relapse or refractory of hematological diseases, septic shock, and the use of mechanical ventilation was independently associated with a poor clinical effectiveness. The univariate analysis of renal insufficiency demonstrated that allogeneic hematopoietic stem cell transplantation, aplastic anemia, and gastrointestinal infection had a statistically significant impact on renal function. Conclusions: The findings of our study demonstrated that CMS was an efficacious treatment for sepsis in Chinese patients with hematological diseases, while concurrently exhibiting an acceptable toxicity profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.